Investor Presentation
December 2021
1
Disclaimer
Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cortexyme's own internal estimates and research. While Cortexyme believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cortexyme believes its internal research is reliable, such research has not been verified by any independent source. This presentation contains information that is highly confidential and/or privileged. The information is intended only for the use of individuals or entities to which it is addressed. If you are not the intended recipient, you are hereby notified that any reliance, disclosure, copying, distribution, or taking of any action on the contents of this material is strictly prohibited. This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Cortexyme's current beliefs, expectations and assumptions regarding the future of its business, its future plans and strategies, its clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, current and prospective markets or products, clinical activities, regulatory approvals, degree of market acceptance, and plans and objectives of management for future operations, are forward- looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward- looking statements contain these identifying words. The forward-looking statements in this presentation represent Cortexyme' views as of the date of this presentation. Although Cortexyme believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, Cortexyme do not plan to publicly update or revise any forward-looking statements contains herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward- looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. There can be no assurance that the opportunity will meet an individual's investment objectives, or that the investor will receive a return of all or part of such investment. Investment results may vary significantly over any given time period. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Cortexyme recommends that investors independently evaluate specific investments and strategies.
2
Evidence Based Approach Focused Upstream
Disruptive MOA
Lead Asset in
Alzheimer's
Phase 3
Expanding Evidence Base
Growing Pipeline
Strong Capital Position
- Atuzaginstat is a proprietary, oral, small molecule with an MOA upstream of neurodegeneration
- Gingipain inhibitor blocks downstream effects of P. gingivalis infection as a driver of Alzheimer's progression
- Novel therapeutic class with supporting clinical data
- Recently completed GAIN Trial supports mechanism of action
- Therapeutic dose, safety profile, and responder population established
- Phase 3 GAIN2 Trial start up and regulatory engagement Q1 2022
- Expanding evidence base with animal causation and human clinical studies
- Data supports expansion into other indications, including Parkinson's disease and periodontal disease
- COR588 is a lysine gingipain inhibitor that began Phase 1 in Q3 2021, data expected H1 2022
- Arginine gingipain inhibitor COR852 advancing to IND enabling studies in 2022
- 3CLpro inhibitor COR803/COR817 advancing to IND enabling studies in 2022
- $140.1M in cash, equivalents, and short-term investments (as of September 30, 2021)
- Fully funded through 2023 to advance through multiple clinical and regulatory milestones
3
Expanding Pipeline
Molecule | Target | Indication | Development Stage | |||
Pre-clinical | Phase 1 | Phase 2 | Phase 3 | |||
Lysine gingipain inhibitor | Alzheimer's disease | |||||
Atuzaginstat | ||||||
(COR388) | ||||||
Lysine gingipain inhibitor | Parkinson's disease | |||||
Periodontal and other | ||||||
COR588 | Lysine gingipain inhibitor | P. gingivalis driven | ||||
disease | ||||||
COR803/ | CL3 Pro inhibitor | COVID-19 and other | ||||
COR817 | coronaviruses | |||||
COR852 | Arginine gingipain | Undisclosed | ||||
inhibitor | ||||||
Undisclosed | Undisclosed | Undisclosed | ||||
4
Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease
Deepak Kumar, *Se Hoon Choi, *Kevin J. Washicosky, *William A. Eimer, Stephanie Tucker, Jessica Ghofrani, Aaron Lefkowitz, Gawain McColl, Lee E. Goldstein, Rudolph E. Tanzi, Robert D. Moir
Alzheimer's Amyloid-b is an antimicrobial peptide: a review of the evidence
Gosztyla, M.G., Brothers, H.M., Robinson, S.R. (2018). Journal
of Alzheimer's Disease, 64(4), 1495- 1506.
The Alzheimer's Disease-Associated
Amyloid β-Protein Is an Antimicrobial
Peptide
Stephanie J. Soscia, James E. Kirby, Kevin J. Washicosky, Stephanie M. Tucker, Martin Ingelsson, Bradley Hyman, Mark A. Burton, Lee E. Goldstein, Scott Duong, Rudolph E. Tanzi, Robert D. Moir
Antimicrobial Properties of
Amyloid Peptides
Bruce L. Kagan, Hyunbum Jang, Ricardo Capone,
Fernando Teran Arce, Srinivasan Ramachandran,
Ratnesh Lal, and Ruth Nussinov
"Could
Alzheimer's Stem From
Infections? It makes sense, experts
say"
Periodontal Disease and Incident
Dementia: The Atherosclerosis Risk
in Communities Study (ARIC)
Ryan T. Demmer, Faye L. Norby, Kamakshi
Lakshminarayan, Keenan A. Walker, James S. Pankow, Aaron R. Folsom, Thomas Mosley, Jim Beck, Pamela L. Lutsey
Tooth loss, dementia and neuropathology in the Nun Study
Pamela Sparks Stein, DMD; Mark Desrosiers, PhD; Sara Jean Donegan, SSND, DDS; Juan F. Yepes, DDS, MD, MPH; Richard J. Kryscio, PhD
Periodontal disease associates with higher brain amyloid load in normal elderly
Angela R. Kamer, Elizabeth Pirraglia, Wai Tsui, Henry Rusinek, Shankar Vallabhajosula, Lisa Mosconi, Li Yi, Pauline McHugh, Ronald G. Craig, Spencer
Tooth loss and Periodontal Disease Predict Poor Cognitive Function in Older Men
Elizabeth Krall Kaye, PhD, Aileen Valencia, BS, Nivine Baba, MA, Avron Spiro, III, PhD, Thomas Dietrich, DMD, and Raul I. Garcia, DMD
Serum antibodies to periodontal pathogens are a risk factor for
Alzheimer's disease
Pamela Sparks Stein, Michelle J. Steffen, Charles Smith, Gregory Jicha, Jeffrey L. Ebersole, Erin Abner, and Dolph Dawson III
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cortexyme Inc. published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 21:51:25 UTC.